Editor’s corner: The year of vaccines for Fierce Pharmanews2021-12-20T20:46:22+00:00December 20th, 2021|Fierce Pharma|
Bluebird bio hits FDA clinical hold—again—for gene therapy in sickle cell diseasenews2021-12-20T15:28:38+00:00December 20th, 2021|Fierce Pharma|
Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspirenews2021-12-20T15:25:11+00:00December 20th, 2021|Fierce Pharma|
Biogen halves Aduhelm’s price and plots cost cuts as Medicare decision on controversial Alzheimer’s drug nearsnews2021-12-20T14:00:08+00:00December 20th, 2021|Fierce Pharma|
Novo Nordisk’s weight loss drug Wegovy to run short amid contract manufacturer hiccupnews2021-12-20T13:50:36+00:00December 20th, 2021|Fierce Pharma|
After EMA recommendation, Novavax’s COVID-19 vaccine nears rollout in Europenews2021-12-20T12:54:55+00:00December 20th, 2021|Fierce Pharma|
Eli Lilly finds embarrassment main cause of underreporting of symptoms in ulcerative colitisnews2021-12-20T12:20:10+00:00December 20th, 2021|Fierce Pharma|
Eli Lilly finds embarrassment main cause of underreporting of symptoms in ulcerative colitisnews2021-12-20T12:20:10+00:00December 20th, 2021|Fierce Pharma|
GlaxoSmithKline reveals health fears of eosinophilic asthma patients, frustration of late diagnosisnews2021-12-20T10:19:03+00:00December 20th, 2021|Fierce Pharma|
GlaxoSmithKline reveals health fears of eosinophilic asthma patients, frustration of late diagnosisnews2021-12-20T10:19:03+00:00December 20th, 2021|Fierce Pharma|
